Integra LifeSciences (NASDAQ:IART) Downgraded by Oppenheimer to "Market Perform"

Oppenheimer cut shares of Integra LifeSciences (NASDAQ:IART - Free Report) from an outperform rating to a market perform rating in a research report released on Tuesday morning, MarketBeat reports.

IART has been the topic of a number of other research reports. JMP Securities cut their price objective on shares of Integra LifeSciences from $55.00 to $49.00 and set a market outperform rating on the stock in a research report on Thursday, February 29th. Wells Fargo & Company lowered Integra LifeSciences from an overweight rating to an equal weight rating and cut their price target for the stock from $45.00 to $25.00 in a report on Tuesday. Citigroup upgraded Integra LifeSciences from a sell rating to a neutral rating and set a $38.00 price objective for the company in a report on Wednesday, April 3rd. Truist Financial lowered their target price on Integra LifeSciences from $46.00 to $41.00 and set a hold rating on the stock in a research report on Friday, March 1st. Finally, StockNews.com downgraded shares of Integra LifeSciences from a buy rating to a hold rating in a research report on Tuesday, April 30th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Integra LifeSciences presently has an average rating of Hold and a consensus target price of $36.80.

Integra LifeSciences Trading Up 8.4 %

NASDAQ IART traded up $1.94 during trading hours on Tuesday, hitting $25.08. 4,165,878 shares of the company's stock were exchanged, compared to its average volume of 811,270. The firm has a market cap of $1.97 billion, a price-to-earnings ratio of 29.94, a PEG ratio of 0.87 and a beta of 1.17. The stock has a 50-day simple moving average of $33.33 and a 200 day simple moving average of $38.33. The company has a current ratio of 3.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.94. Integra LifeSciences has a 1-year low of $22.36 and a 1-year high of $51.12.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings data on Monday, May 6th. The life sciences company reported $0.55 EPS for the quarter, hitting the consensus estimate of $0.55. Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The company had revenue of $368.90 million during the quarter, compared to the consensus estimate of $361.96 million. During the same quarter last year, the firm posted $0.74 EPS. The company's quarterly revenue was down 3.2% on a year-over-year basis. On average, equities analysts forecast that Integra LifeSciences will post 3.19 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in IART. Signaturefd LLC increased its stake in Integra LifeSciences by 248.5% in the 4th quarter. Signaturefd LLC now owns 582 shares of the life sciences company's stock valued at $25,000 after buying an additional 415 shares during the last quarter. Hexagon Capital Partners LLC boosted its position in Integra LifeSciences by 123.3% during the fourth quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company's stock worth $29,000 after purchasing an additional 370 shares during the period. Gladius Capital Management LP purchased a new position in shares of Integra LifeSciences in the third quarter worth about $47,000. Valley National Advisers Inc. bought a new stake in shares of Integra LifeSciences in the first quarter valued at approximately $63,000. Finally, Covestor Ltd lifted its stake in shares of Integra LifeSciences by 82.5% during the 3rd quarter. Covestor Ltd now owns 2,037 shares of the life sciences company's stock valued at $78,000 after buying an additional 921 shares in the last quarter. 84.78% of the stock is owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.